The Systematic Comparison of Enhancer of Zeste Homolog-2-, Bromodomain-containing Proteins-, Histone Deacetylase-, and DNA-methyltransferase 1-inhibitors in a Syngeneic Murine Model of Melanoma Reveals Differential Anti-tumoral and Immunomodulatory Activities

Valentina Rigo; Adriana Amaro; Francesco Reggiani; Daniela Fenoglio; Stefania Martini; Tiziana Altosole; Mariangela Petito; Cecilia Profumo; Michela Croce

doi:10.1002/mco2.70336

MedComm ›› 2025, Vol. 6 ›› Issue (8) : e70336 DOI: 10.1002/mco2.70336

LETTER

The Systematic Comparison of Enhancer of Zeste Homolog-2-, Bromodomain-containing Proteins-, Histone Deacetylase-, and DNA-methyltransferase 1-inhibitors in a Syngeneic Murine Model of Melanoma Reveals Differential Anti-tumoral and Immunomodulatory Activities

Author information +

History +

PDF

Cite this article

Download citation ▾

Valentina Rigo, Adriana Amaro, Francesco Reggiani, Daniela Fenoglio, Stefania Martini, Tiziana Altosole, Mariangela Petito, Cecilia Profumo, Michela Croce. The Systematic Comparison of Enhancer of Zeste Homolog-2-, Bromodomain-containing Proteins-, Histone Deacetylase-, and DNA-methyltransferase 1-inhibitors in a Syngeneic Murine Model of Melanoma Reveals Differential Anti-tumoral and Immunomodulatory Activities. MedComm, 2025, 6(8): e70336 DOI:10.1002/mco2.70336

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	L. Sun, H. Zhang, and P. Gao, “Metabolic Reprogramming and Epigenetic Modifications on the Path to Cancer,” Protein Cell 13, no. 12 (2022): 877-919.

[2]	A. Anichini, A. Molla, G. Nicolini, et al., “Landscape of Immune-related Signatures Induced by Targeting of Different Epigenetic Regulators in Melanoma: Implications for Immunotherapy,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 325.

[3]	A. Amaro, F. Reggiani, D. Fenoglio, et al., “Guadecitabine Increases Response to Combined Anti-CTLA-4 and Anti-PD-1 Treatment in Mouse Melanoma in Vivo by Controlling T-cells, Myeloid Derived Suppressor and NK Cells,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 67.

[4]	Y. C. Cheuk, S. Xu, D. Zhu, et al., “Monocytic Myeloid-Derived Suppressor Cells Inhibit Myofibroblastic Differentiation in Mesenchymal Stem Cells through IL-15 Secretion,” Frontiers in Cell and Developmental Biology 10 (2022): 817402.

[5]	J. Banchereau and R. M. Steinman, “Dendritic Cells and the Control of Immunity,” Nature 392, no. 6673 (1998): 245-252.

[6]	Y. Yang and A. Lundqvist, “Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy,” Cancers 12, no. 12 (2020): 3586.

[7]	M. Boi, E. Gaudio, P. Bonetti, et al., “The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes With Targeted Drugs,” Clinical Cancer Research 21, no. 7 (2015): 1628-1638.

[8]	M. Tekguc, J. B. Wing, M. Osaki, J. Long, and S. Sakaguchi, “Treg-expressed CTLA-4 Depletes CD80/CD86 by Trogocytosis, Releasing Free PD-L1 on Antigen-presenting Cells,” PNAS 118, no. 30 (2021).

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.